Understanding Morquio Syndrome (MPS IV)

Receiving a diagnosis of Morquio Syndrome (MPS IV) for yourself or your child can feel overwhelming, but it is the first step toward accessing specialized care and community support. While Morquio is a rare and life-changing condition, it is a well-studied disorder with established care protocols and advancing treatment options ^[1][2].

What is Morquio Syndrome?

Morquio Syndrome, also known as Mucopolysaccharidosis IV (MPS IV), is an autosomal recessive lysosomal storage disorder ^[3]. This means that to have the condition, an individual must inherit one copy of a specific mutated gene from each parent ^[1].

Inside the body, there are recycling centers called lysosomes that use proteins called enzymes to break down waste ^[1]. In Morquio Syndrome, one of these enzymes is either missing or not working correctly ^[3]. As a result, specific complex sugar molecules called glycosaminoglycans (GAGs)—specifically keratan sulfate—cannot be broken down ^[3][1]. These sugars build up in the body’s tissues, particularly in the bones, cartilage, and heart valves, leading to the physical symptoms of the condition ^[1][4].

Understanding Type A and Type B

There are two forms of Morquio Syndrome, distinguished by which specific enzyme is missing.

While symptoms can still be significant in Type B, it generally presents with less severe skeletal involvement than Type A ^[1][5]. Despite being rare, Morquio Syndrome is frequently diagnosed and treated compared to other types of MPS disorders ^[6].

Three Stabilizing Facts

As you navigate this diagnosis, keeping these three core facts in mind can help ground the journey:

1. Intelligence is Typically Normal: Unlike many other MPS disorders that affect the brain, Morquio Syndrome is primarily a skeletal and systemic condition ^[1]. Individuals with Morquio typically have normal cognitive development and intelligence, meaning they can participate fully in school, work, and social life with the right physical accommodations ^[1][7].
2. Specialized Treatments are Available: There is an FDA-approved Enzyme Replacement Therapy (ERT) called elosulfase alfa (Vimizim) specifically for Type A ^[8]. This treatment helps replace the missing enzyme, which has been shown to improve endurance, respiratory function, and overall quality of life ^[8][9].
3. Proactive Care Extends Life and Health: While the condition is progressive, life expectancy varies widely based on severity. Historically, classical severe MPS IVA has been associated with a significantly shorter life expectancy (often 20s to 30s) due to respiratory and spinal complications ^[2]. However, individuals with milder (attenuated) phenotypes, Type B, or those who benefit from modern surgical interventions and multidisciplinary care are increasingly living well into their 50s, 60s, and beyond ^[2][10].

Moving Forward with Your Care Team

Managing Morquio Syndrome requires a proactive, “eyes-wide-open” approach. Early diagnosis allows your medical team to monitor critical areas, such as the cervical spine (the neck) and the respiratory system, to prevent long-term damage ^[11][2]. Your role is to be the coordinator of this team, ensuring that every specialist is looking at the whole person rather than just one symptom ^[12]. While the road ahead is complex, you are not walking it alone; a global community of researchers and families is dedicated to improving life with Morquio Syndrome.